What Dialectic Therapeutics does

Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs based on its proprietary Antiapoptotic Protein Targeted Degradation (APTaD™) platform. The platform selectively induces cancer cells to degrade antiapoptotic proteins of the BCL-2 family — most notably BCL-XL — thereby stimulating cancer cell apoptosis or sensitizing tumors to chemotherapy while sparing platelets. The lead clinical candidate, DT2216, is a BCL-XL-targeting degrader currently in Phase 1/2 clinical trials across multiple oncology indications: relapsed/refractory peripheral and cutaneous T-cell lymphoma, fibrolamellar carcinoma, and platinum-resistant ovarian cancer. The company has secured FDA Fast Track Designation and Orphan Drug Designation for DT2216 in T-cell lymphoma, and protects its platform through three issued US patents plus corresponding foreign filings.

Dialectic was founded in 2018-2019 in Dallas, Texas by three cancer scientists and two biotech operators, with scientific co-founders drawn from the University of Florida and UT Health San Antonio. The company operates as a virtual-capable biotech, with research partnerships at UT Health San Antonio and the University of Florida Health Cancer Center, and clinical trial collaborations including with Dana-Farber Cancer Institute. Leadership combines pharmaceutical R&D experience (CSO Larry Tremaine, formerly of Pfizer) with serial biotech entrepreneurship (Executive Chairman John Harkey, co-founder of AveXis acquired by Novartis for $8.7B in 2018).

The business model is pre-commercial: Dialectic is privately held, pre-revenue, and funds its development through grants and equity financing rather than product sales. To date the company has raised approximately $19.9M, predominantly from Cancer Prevention and Research Institute of Texas (CPRIT) grants totaling $17.4M. The company employs 1-10 people. Future revenue is expected to derive from pharmaceutical product sales or one-time licensing transactions following regulatory approval of DT2216 or successor compounds. Customer/end-user focus is on oncology patients with limited treatment options whose tumors overexpress antiapoptotic BCL-2 family proteins.

Name

Dialectic Therapeutics

Legal name

Dialectic Therapeutics, Inc.

Website

https://dtsciences.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Dialectic Therapeutics is a Dallas-based clinical-stage biotechnology company developing anti-cancer drugs via its proprietary APTaD platform that selectively degrades antiapoptotic proteins like BCL-XL, with lead candidate DT2216 in Phase 1/2 trials for T-cell lymphoma, fibrolamellar carcinoma, and platinum-resistant ovarian cancer.

Ownership category

akta.pro rank

Product category

Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Targeted protein degradation
• Anticancer drug development
• Oncology clinical trials
• BCL-XL inhibitors
• PROTAC therapeutics

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing anti-cancer drugs. Revenue will be generated through future pharmaceutical product sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Dialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its proprietary Antiapoptotic Protein Targeted Degradation (APTaD™) platform, which selectively induces cancer cells to degrade antiapoptotic proteins such as BCL-XL, stimulating cancer cell death or sensitization to chemotherapy. Its lead clinical candidate, DT2216, is a first-generation APTaD compound currently in Phase 1/2 clinical trials for fibrolamellar carcinoma, platinum-resistant ovarian cancer, and T-cell lymphoma.

Product overview

Dialectic Therapeutics is a clinical-stage biotechnology company developing innovative anti-cancer drugs through its proprietary Antiapoptotic Protein Targeted Degradation (APTaD™) platform. The company's lead product is DT2216, a BCL-XL degrader currently in Phase 1/2 clinical trials for multiple oncology indications including Fibrolamellar Carcinoma, Platinum-Resistant Ovarian Cancer, and T-cell lymphoma. DT2216 has received FDA Fast Track Designation for PTCL/CTCL and Orphan Drug Designation for T-cell lymphoma. The APTaD platform enables targeted degradation of antiapoptotic proteins that cancer cells rely on for survival, offering a novel approach to cancer treatment with reduced toxicity compared to traditional chemotherapy.

Differentiator

Problem solved

Functional benefit

Products and services

• DT2216 Lead APTaD compound that selectively induces cancer cells to degrade BCL-XL (B-cell lymphoma extra-large), stimulating cells to commit suicide or become more susceptible to chemotherapy. Currently in Phase 1/2 clinical trials for Fibrolamellar Carcinoma, Platinum-Resistant Ovarian Cancer, and T-cell lymphoma.
• APTaD™ Platform Antiapoptotic Protein Targeted Degradation (APTaD™) technology platform enabling development of compounds that selectively degrade antiapoptotic BCL-2 family proteins. Platform is designed to be applied to BCL-XL, BCL-2, MCL-1 and other antiapoptotic protein targets for cancer treatment.

Quantifiable outcome

• DT2216 achieved tumor eradication in preclinical models of platinum-resistant ovarian cancer
• +1 more outcomes

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 19 November 2025Clinical trial collaboration for DT2216 in platinum-resistant ovarian cancer (PROC). Principal investigators include Drs. Elizabeth Stover, Joyce Liu, and Ursula Matulonis. Trial evaluates DT2216 in combination with paclitaxel for patients who have exhausted available treatment options.
• UT Health at San AntoniocoreStrategic or Co-development PartnerResearch partnership and collaboration with University of Texas Health Science Center at San Antonio. Dr. Daohong Zhou serves as professor and co-director at UTHSA. The institution houses research facilities and scientific expertise supporting Dialectic's drug development programs.
• University of Florida Health Cancer CentercoreStrategic or Co-development PartnerResearch partnership with University of Florida College of Pharmacy. Scientific co-founders Dr. Guangrong Zheng (Associate Professor, Medicinal Chemistry) and Dr. Daohong Zhou (before UTHSA) conducted foundational research at UF. Published multiple studies on BCL-XL targeting and APTaD technology.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dialectictherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dialectic Therapeutics